89bio initiates Phase 3 ENLIGHTEN trial for pegozafermin, a potential MASH treatment, in non-cirrhotic fibrosis patients.

89bio begins Phase 3 ENLIGHTEN trial for pegozafermin, a potential treatment for metabolic dysfunction-associated steatohepatitis (MASH), in non-cirrhotic patients with fibrosis stages F2-F3. The ENLIGHTEN program aims for accelerated approval in the U.S. and conditional approval in Europe. The trial will have 1,000 patients in a 1:1:1 ratio on pegozafermin doses or placebo.

March 12, 2024
3 Articles

Further Reading